Gilead Emtriva approval
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Gilead Sciences' Emtriva (emtricitabine, formerly Coviracil) clears FDA July 2 as the agency's third new molecular entity approval for HIV in 2003. The once-daily nucleoside reverse transcriptase inhibitor is indicated for combination use with other antiretroviral agents for the treatment of HIV-1 infection in adults; labeling adds that in treatment-experienced patients, Emtriva can be used when HIV strains are expected to be susceptible based on genotypic/phenotypic testing. Gilead, which gained Emtriva via its January acquisition of Triangle, hopes to launch a fixed-dose combo of Emtriva and its nucleotide reverse transcriptase inhibitor Viread (tenofovir) in early 2005. Gilead also plans to initiate a study comparing a regimen of Emtriva, Viread and efavirenz to GSK's Combivir and efavirenz by year-en
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.